BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29739098)

  • 1. Comparison of a Newly Developed HPV Genotyping Assay (Mojin HPV Kit) with Cobas 4800 HPV Test for Detection of High-Risk HPV in Specimens Collected in SurePath Solution.
    Yang WW; Wang ZG; Chen GF; Shi JF; Chen J; Ma QH; Zhou J; Mao XD; Liu C; Yao XM
    Clin Lab; 2018 Mar; 64(3):387-391. PubMed ID: 29739098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.
    Yu S; Kwon MJ; Lee EH; Park H; Woo HY
    J Med Virol; 2015 Sep; 87(9):1587-93. PubMed ID: 25914215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of cobas 4800 high-risk HPV test as a tool in cervical cancer screening and cytology triage].
    Chen W; Yu LL; Wang H; Fu CJ; Chen F; Cao YQ; Kang LN; Zhang X; Zhao FH; Geng L; Yu L
    Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):543-8. PubMed ID: 22967475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology.
    Pesic A; Krings A; Hempel M; Preyer R; Chatzistamatiou K; Agorastos T; Kaufmann AM
    Virol J; 2019 Jul; 16(1):92. PubMed ID: 31337408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test.
    Schiffman M; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Apple R; Aldrich C; Erlich HA; Tam T; Befano B; Burk RD; Castle PE
    Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1304-10. PubMed ID: 26088703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
    Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
    J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.
    Preisler S; Rebolj M; Ejegod DM; Lynge E; Rygaard C; Bonde J
    BMC Cancer; 2016 Jul; 16():510. PubMed ID: 27439470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.
    Wong OGW; Ng IFY; Tsun OKL; Pang HH; Ip PPC; Cheung ANY
    J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31511337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A direct comparison of four high-risk human papillomavirus tests versus the cobas test: Detecting CIN2+ in low-resource settings.
    Xue P; Gao LL; Yin J; Han LL; Zhao J; Li L; Seery S; Han XY; Li TY; Jiang Y; Chen W; Shen J
    J Med Virol; 2019 Jul; 91(7):1342-1350. PubMed ID: 30854653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.
    Demarco M; Carter-Pokras O; Hyun N; Castle PE; He X; Dallal CM; Chen J; Gage JC; Befano B; Fetterman B; Lorey T; Poitras N; Raine-Bennett TR; Wentzensen N; Schiffman M
    J Clin Microbiol; 2018 May; 56(5):. PubMed ID: 29491018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
    Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
    Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.
    Wong OGW; Tsun OKL; Tsui EY; Chow JNK; Ip PPC; Cheung ANY
    J Clin Virol; 2018 Dec; 109():13-18. PubMed ID: 30368218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
    Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
    Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
    Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
    J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.
    Mariano VS; Lorenzi AT; Scapulatempo-Neto C; Stein MD; Resende JC; Antoniazzi M; Villa LL; Levi JE; Longatto-Filho A; Fregnani JH
    PLoS One; 2016; 11(10):e0164892. PubMed ID: 27764154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.